Wed, May 2, 2018

Advanced manufacturing is getting a big boost with a new round of investment in NuMat Technologies, which is creating intelligently engineered systems through the integration of programmable nanomaterials. Closing a $12.4 million financing round led by OS Fund, with participation by Osage University Partners, Tin Shed Ventures (Patagonia’s strategic investment arm), and other existing investors, NuMat is poised to expand the global reach of its molecularly engineered products platform to Europe, East Asia and beyond.

“We’re thrilled to partner with OS Fund and Osage University Partners to realize NuMat’s vision of commercializing molecularly engineered products that enable paradigm shifts in how we create and use resources,” said Benjamin Hernandez, NuMat’s co-founder and CEO. “These investments allow NuMat to solidify its technology leadership position as an integrator of choice for metal-organic frameworks. We’re proud to be a U.S. Midwestern company manufacturing IP-intensive products for global markets.”

Mon, February 26, 2018

The American Society for Parenteral and Enteral Nutrition (ASPEN) and Fresenius Kabi announced a new educational video series highlighting best practices for dosing, preparing and administering intravenous lipid emulsions (ILE). Designed for clinicians who provide nutrition support, the series address a knowledge gap between best practice recommendations and current practices in parenteral nutrition (PN).  "Lipids provide energy and essential fatty acids, and ASPEN's survey results demonstrate a need for a better understanding of ILE provision in current practice,"said Seema Kumbhat, M.D., senior vice president and regional medical director at Fresenius Kabi in North America. "This video series is designed to educate healthcare providers on ILE best practices, such that optimal nutrition can be delivered to patients who need it.'  For more on this series, click here.

Remifentanil Hydrochloride for Injection CII Now Available : First-to-Market Alternative to ULTIVA® "Fresenius Kabi has been investing significantly in product development over the last several years, and plans to launch multiple generic injectable products in the U.S. this year," said John Ducker, president and CEO of Fresenius Kabi USA.  For the press release, click here

Bortezomib for Injection: First available IV administration alternative to VELCADE® Bortezomib for Injection for intravenous use is indicated for the treatment of patients with multiple myeloma and for the treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy.  Tor the press release, click here.


February 2018

New from Fresenius Kabi

The American Society for Parenteral and Enteral Nutrition (ASPEN) and Fresenius Kabi announced a new educational video series highlighting best... Read on >

January 2018

Exicure Funding

Exicure, Inc. announced the closing of approximately $11.2 million in subsequent financing led by Luye Pharma Group and others including Eager... Read on >

August 2017

NuMat Technologies & Versum Materials

Versum Materials, Inc., a leading global materials supplier to the semiconductor industry, and NuMat Technologies, a pioneer in the design and... Read on >

July 2017

Check out Mid Year SKOKIEBIZ

2017 has brought several new notable rankings for the Village.  ... Read on >